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Are interleukin-16 and thrombopoietin new tools for the in vitro generation of
dendritic cells?
Silvia Della Bella, Stefania Nicola, Inna Timofeeva, Maria Luisa Villa, Armando Santoro, and Anna C. Berardi
The effects of interleukin 16 (IL-16) on
dendritic cell (DC) generation from hu-
man CD34 progenitor cells are not
known. Here, we show that IL-16 added to
a basal cocktail comprised of granulocyte-
macrophage colony-stimulating factor
(GM-CSF), IL-4, Flt-3 ligand (Flt3L), and
tumor necrosis factor  (TNF-) does
induce the CD34 hematopoietic cells to
proliferate in vitro and to differentiate into
phenotypically and functionally mature
DCs. IL-16 exerts this function more effi-
ciently than stem cell factor (SCF) as a
control, thrombopoietin (TPO), or IL-16
plus TPO. Moreover, we show that the
combination of IL-16 plus TPO induces
the generation of tolerogenic DCs, able to
induce an anergic state in T cells that
persists when T cells are rechallenged
with immunogenic DCs. An altered pat-
tern of cytokine production, a reduced
expression of the C-type lectin DC-SIGN,
and an increased surface expression of
the inhibitory molecules immunoglobulin-
like transcript 2 (ILT-2), ILT-3, and ILT-4
may all contribute to confer the tolero-
genic properties of these DCs. Genera-
tion of tolerogenic DCs may aid the explo-
ration of new therapeutic strategies to
promote tolerance to autoantigens and
prevent disease development. (Blood.
2004;104:4020-4028)
© 2004 by The American Society of Hematology
Introduction
Dendritic cells (DCs) are professional antigen-presenting cells
(APCs), able to induce primary T-cell activation, polarization, and,
in certain circumstances, tolerance.1-3 Immature DCs in the periph-
ery capture antigens and then, through inflammatory stimuli,
migrate to draining lymph nodes where they present processed
antigens to naive T cells.3,4 At this more mature stage of their life,
DCs up-regulate expression of major histocompatibility (MHC)
class II as well as costimulatory molecules, such as CD40, CD80,
and CD86.5 The ability of DCs to initiate immune responses has
focused much attention on the potential use of DCs for immuno-
therapy. Progress in the understanding of DC biology has been
made slowly and with difficulty because of the paucity of these
cells in the peripheral blood and in other tissues. In recent years,
several investigators successfully generated in vitro human DCs
from human peripheral blood monocytes and from human CD34
cells obtained from various sources such as peripheral blood, cord
blood, or bone marrow, by culture with multiple cytokine combina-
tions. Standard monocyte-derived DCs are obtained by culture of
monocytes in the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 5 to 7
days. DCs with immune properties similar to those of mature
monocyte-derived DCs can be generated from CD34 progenitors
using combinations of the cytokines stem cell factor (SCF), Flt-3
ligand (Flt3L), GM-CSF, IL-4, and tumor necrosis factor–
(TNF-), in cultures lasting 14 days.6 In this model system, SCF
and Flt3L support the development of hematopoietic progenitors,7,8
whereas GM-CSF, IL-4, and TNF- promote the differentiation
into DCs.9-10 The use of cytokines other than SCF and Flt3L to
expand hematopoietic progenitors could represent a good strategy
to improve the system, aimed to obtain larger numbers of cultured
DCs that can be used to better define DC biology and for
immunotherapeutic purposes.
IL-16 in its biologically active form is a cationic homotetramer
of 14-kDa chains, which is unrelated to previously described
chemokines or other chemotactic or growth factor cytokines.10,11
IL-16 is a chemotactic and activating factor for CD4 T cells,
monocytes, eosinophils, and DCs. The biologic activities of IL-16
depend on the cell surface expression of CD4,12-14 through which
IL-16 conveys its functional signal.13,14 It has been reported that a
subpopulation of CD34 hematopoietic cells expresses CD4 on its
surface; it has been suggested that this population may be
represented by very early cells.15 Therefore, we were interested in
exploring whether IL-16 may be a possible candidate cytokine able to
induce CD34 cells to proliferate or differentiate versus DC lineage.
Human stem cells also express the receptor for thrombopoietin
(TPO) on their surface.16 TPO is a factor endowed with the ability
to induce the proliferation of primitive hematopoietic progenitor
cells17; when combined with Flt3L and SCF, TPO not only induces
the generation of long-lasting DC precursors from CD34 cells, but
also seems to condition the irreversible commitment of CD14
cells into monocytic lineage.18,19
In the present report we provide evidence, for the first time to
our knowledge, that IL-16 in combination with Flt3L, GM-CSF,
IL-4, and TNF- can induce CD34 hematopoietic cells to
proliferate in vitro and to differentiate into phenotypically and
functionally mature DCs. IL-16 exerts this function more effi-
ciently than SCF or TPO or IL-16 plus TPO. Moreover, the
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combination of IL-16 plus TPO induces the generation of tolero-
genic DCs, able to induce an anergic state in T cells that persists
when T cells are rechallenged with immunogenic DCs. An altered
pattern of cytokine production, a reduced expression of the C-type
lectin DC-SIGN, and an increased surface expression of the
inhibitory molecules immunoglobulin-like transcript–2 (ILT-2),
ILT-3, and ILT-4 may all contribute to confer the tolerogenic
properties of these DCs.
Materials and methods
Isolation of human CD34 cell progenitors
Leukapheresis products were obtained from healthy donors and from
patients with solid tumors undergoing peripheral blood stem cell (PBSC)
mobilization with recombinant human granulocyte-colony stimulating
factor (G-CSF) after informed consent was provided. Approval for these
studies was obtained from the Instituto Clinical Humanitas institutional
review board. Leukapheresis samples contained 0.5% to 9.1% CD34 cells.
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll
density gradient centrifugation (Ficoll-Hypaque, Pharmacia Biotech, Upp-
sala, Sweden). CD34 cells were purified using immunomagnetic selection
with mini–magnetic-activated cell sorter (MACS) cell isolation kit (Mil-
tenyi Biotec, Bergisch Gladbach, Germany) according to the manufactur-
er’s instructions.
Generation of DCs from CD34 progenitor cell cultures
CD34-enriched cells (mean purity 90.0%  8.4%) were cultured in
25-cm2 flasks at 1  105/mL for 14 days in RPMI 1640 (Gibco Laborato-
ries, Milan, Italy), supplemented with 10% heat-inactivated fetal calf serum
(FCS; Euroclone, Wetherby, United Kingdom), in the presence of a basal
cocktail, comprised of human recombinant GM-CSF (50 ng/mL), IL-4 (10
ng/mL), Flt3L (50 ng/mL), TNF- (2.5 ng/mL), plus either SCF (10 ng/mL;
SCF-DCs), or TPO (10 ng/mL; TPO-DCs), or IL-16 (10 ng/mL; IL-16-
DCs), or IL-16 plus TPO (IL-16/TPO-DCs). All the cytokines were from
PeproTech (London, United Kingdom). Each 3 days, half of the culture
medium was replaced by fresh medium and growth factors. At the end of the
culture, cells were collected and used for subsequent analysis. The cell
morphology was assessed on cytospin preparations after May-Gru¨nwald-
Giemsa or acridine orange (AO) staining. The peak of DC production
occurred at day 14.
Cell sorting
Cell sorting of the CD34CD4 and CD34CD4 cells was performed
starting from magnetic bead-isolated CD34 cells. Purified CD34 cells
(1  106 cells) were isolated simultaneously with fluorescein isothiocya-
nate (FITC; CD34) and phycoerythrin (PE; CD4) using a modified dual
laser fluorescence-activated cell sorter (FACS) Vantage (Becton Dickinson,
San Jose, CA). Dead cells were excluded from cytometric analysis by
propidium iodide (PI) staining. The mean purity of the sorted cells was
always more than 99% for the indicated surface marker phenotype.
Immunophenotypic analysis
DCs were incubated with different FITC- or PE-conjugated monoclonal
antibodies (mAbs) for 30 minutes at 4°C in the dark. The following mAbs
were used: anti-CD1a, -CD3, -CD4, -CD14, -CD15, -CD19, -CD34,
-CD40, -CD41, -CD80, -CD83, -CD86, –HLA-ABC, –HLA-DR (Becton
Dickinson); -CD11c (Caltag, Burlingame, CA); -CD123 (PharMingen, San
Diego, CA); -CD209 (DC-SIGN; R&D Systems, Minneapolis, MN); and
–ILT-2, –ILT-3, –ILT-4 (a generous gift of Prof E. Berti, University of
Milano-Bicocca, Italy). Negative controls were isotype-matched irrelevant
mAbs. Cells were collected and analyzed using a FACScan (Becton
Dickinson) flow cytometer. Data analysis was performed by CellQuest
software (Becton Dickinson). Cells were electronically gated according to
light scatter properties to exclude cell debris.
Mannose receptor-mediated endocytosis
FITC-dextran (Molecular Probes, Eugene, OR) was used to assess cell
endocytosis, as described elsewere.20 Briefly, 1  105 cells were incubated
with 1 mg/mL FITC-dextran at 37°C or 0°C for 60 minutes. Samples were
extensively washed prior to flow cytometry analysis. The level of antigen
uptake by DCs was expressed as the difference in mean fluorescence intensity
(MFI) between the test (37°C) and control (0°C) tubes for each sample.
Phagocytosis of apoptotic cells
The ability of DCs to internalize apoptotic cells was assessed as described
elsewere.20 Briefly, monocyte-depleted PBMCs were labeled with 0. 5 M
chloro-methyl-fluorescein-diacetate (CMFDA; Molecular Probes) for 30
minutes at 37°C. Cell apoptosis was induced by 24-hour treatment with 10
M H2O2 and assessed by morphology and staining with PI and AO. The
labeled apoptotic cells were subsequently cocultured with CD1a-labeled
allogeneic DCs at a 1:1 ratio. After 2 hours, the cells were washed and
treated with 0.05% trypsin/0.02% EDTA (ethylenediaminetetraacetic acid)
for 5 minutes to disrupt cell-to-cell binding. Phagocytosis was quantified by
flow cytometry as percentage of double-positive cells (CMFDA/CD1a).
Negative controls were performed at 0°C.
Allogeneic and autologous T-cell proliferation assay
To test their allostimulatory activity, DCs (15  103) were cocultured in
96-well plates with 3  105 allogeneic, monocyte-depleted PBMCs in
triplicate for 5 days.20 To test their ability to present soluble antigens to
autologous lymphocytes, DCs were incubated with or without influenza
virus vaccine (FLU) for 24 hours and then cocultured with autologous,
monocyte-depleted PBMCs for 7 days. In all cases, 5-bromo-2-
deoxyuridine (BrdU, 20 M; Sigma Chemicals, St. Louis, MO) was added
in each well during the last 6 hours of culture, and lymphocyte proliferation
was assessed by flow cytometry as BrdU incorporation by CD4 lympho-
cytes, as described by Toba et al.21 Results were expressed as percentage of
proliferating (BrdU) lymphocytes.
Tolerance assay
CD45RACD4 naive T lymphocytes, purified as previously described,20
were cocultured with allogeneic SCF-DCs or IL-16/TPO-DCs as for
primary allogeneic cultures. After 5 days, the T cells were harvested,
washed, and rested for an additional 2 days in culture medium, as described
by Nouri-Shirazi and Guinet.22 The rested T cells from primary cultures
were rechallenged in a second proliferation assay with 1.5  104 SCF-DCs,
and proliferation assessed as percentage of BrdU-incorporating lymphocytes.
Cytokine measurements
The release of cytokines in the supernatants of unstimulated DCs was
determined by a specific enzyme-linked immunosorbent assay (ELISA). To
this aim, CD34 cells were plated at 2.5  105/mL in 24-well plates and
cultured as described (see “Generation of DCs from CD34 progenitor cell
cultures”). Supernatants were harvested at the indicated time points, and the
concentration of IL-10, IL-12p70, and interferon-	 (IFN-	) was measured
by use of commercially available pairs of mAbs (Endogen, Woburn, MA).
Transforming growth factor–
 (TGF-
) and IFN- were measured with
TGF-
1 Quantikine (R&D Systems) and IFN- ModuleSet (Bender
MedSystems, Vienna, Austria), respectively, used according to the manufac-
turers’ instructions.
The production of cytokines by T cells cocultured with allogeneic DCs
was determined by flow cytometry as intracellular cytokine expression, as
previously described.20 Briefly, after the indicated days of DC-T coculture,
T cells were reactivated with 12-myristate-13-acetate (PMA; 25 ng/mL)
plus ionomycin (1 g/mL) for 5 hours. Brefeldin-A (BFA; 10 g/mL;
Sigma) was added during the last 4 hours to accumulate most of the
cytokine in the Golgi complex. Cells were labeled with CD4 mAb, fixed,
and permeabilized using Fix&Perm (Caltag), and then labeled with mAb
against cytokine IL-2, IFN-	, or IL-10.
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Statistical analysis
Statistical analysis was performed with Openstat 3 software (open source
statistics package by Bill Miller, Iowa State University).
Results
Cell proliferation and differentiation in cultures of CD34
progenitor cells
CD34 fractions ranging in purity from 80% to 92% were cultured
for 2 weeks in the presence of Flt3L, GM-CSF, IL-4, TNF- (basal
cocktail) plus either SCF as a control, IL-16, TPO, or IL-16 plus
TPO. In the presence of IL-16 the total number of in vitro expanded
cells was higher (fold increase, mean  SEM, 19.04  3.24) than
in the presence of the other growth factors, namely, SCF
(10.84  2.01; P  .016), TPO (11.86  2.79; P  .051), or IL-16
plus TPO (14.89  3.03; P not significant; Figure 1A). No
differences were observed between cultures of samples collected
from healthy donors or patients. Exposure of CD34 cells to the 4
cytokine combinations led to progressive appearance of typical DC
morphology. After 14 days of culture, the majority of the cells
showed lobulated nuclei and numerous fine cytoplasmic projec-
tions, as assessed by May-Gru¨nwald-Giemsa staining, and con-
firmed by fluorescence microscopy after AO staining (Figure 1B).
IL-16 appeared to be more efficient than the other factors in
inducing the differentiation of CD34 cells into DCs because the
cells grown in the presence of IL-16 showed a more rapid and
efficient down-regulation of CD34 and surface expression of the
DC marker CD1a (Figure 1C; Table 1). After 7 days of culture, the
percentage of cells still expressing CD34 was significantly lower in
Figure 1. Cell proliferation and differentiation of
CD34 progenitor cells in different culture condi-
tions. (A) After 14 days, the total number of cells
expanded in vitro in the presence of IL-16 added to the
basal cocktail was higher than in the presence of the
other cytokine combinations. The mean fold increase
over cell number plated on day 0 is shown. Mean SEM
from 16 independent experiments. Comparison between
treatments performed with the 2-tailed t test. (B) Morphol-
ogy of the cells after 14 days of culture. The majority of
the cells showed lobulated nuclei and numerous fine
cytoplasmic projections, as assessed by AO staining.
Photographs were taken under a Leitz-DIALUX22 fluores-
cence microscope (Leica, Milan, Italy) equipped with a
Kodak DX7590 camera (Kodak-italia, Milan, Italy). Original
magnification  400. No differences were observed among
the different culture conditions. (C) Down-regulation of CD34
and up-regulation of CD1a expression after 7 and 14 days of
culture in the presence of the different cytokine combinations.
IL-16 () added to the basal cocktail (‚) appeared to be
more efficient than SCF (Œ), TPO (F), and IL-16 plus TPO
(f) in inducing the differentiation of CD34 cells into DCs.
The mean of 9 independent experiments is shown. (D) After
14 days, the number of DCs expanded in vitro in the
presence of IL-16 added to the basal cocktail was higher than
in the presence of the other cytokine combinations. The mean
fold increase,obtainedbymultiplying thepercentageofCD1a
cells for the absolute number of viable cells, is shown. Mean
SEM from 16 independent experiments. Comparison
between treatments performed with the 2-tailed t test.
Table 1. Immunophenotypic pattern of CD34-derived DCs obtained under different culture conditions
Marker BC, %
BCSCF,*
%
BCIL-
16,† %
BCTPO,†
%
BCIL-
16TPO,†
% BC, MFI BCSCF,* MFI
BCIL-16,†
MFI BCTPO,† MFI
BCIL-16TPO,†
MFI
CD34 6.3 1.2 1.0 0.6‡ 0.8 0.3 2.5 0.6‡ 1.4 0.8 17.6 2.9 6.8 1.8‡ 4.5 1.2§ 9.4 2.3§ 8.3 2.1
CD14 0.2 0.1 0.5 0.4 0.3 0.2 0.3 0.1 0.4 0.1 2.9 0.4 3.4 0.6 2.8 0.3 2.7 0.5 3.7 0.4
CD1a 78.5 11.2 79.1 7.4 93.0 3.1‡ 87.1 5.7‡ 80.0 6.5 134.6 11.3 287.1 124.5 342.8 182.1 294.2 86.9 210.7 78.8
CD80 79.3 8.1 82.9 3.5 96.3 2.2‡ 87.7 5.8§ 89.7 5.4‡ 814.3 51.6 844.5 115.3 1004.0 70.0§ 970.1 110.2§ 982.3 75.7§
CD86 52.9 2.3 58.0 8.7 66.6 7.5§ 68.0 7.7‡ 66.3 7.3§ 273.6 43.3 402.1 103.4§ 795.4 38.1‡ 567.3 119.1‡ 570.6 29.3‡
CD40 8.2 0.2 8.4 1.7 19.5 1.1‡ 8.6 1.0 10.7 1.6§ 35.6 3.7 37.0 3.1 71.2 3.2‡ 47.3 4.6‡ 44.5 9.4§
CD83 3.1 1.0 2.5 0.7 12.3 0.6‡ 6.1 1.8‡ 6.2 1.9‡ 21.6 6.7 23.0 7.2 57.7 4.5‡ 39.4 4.4‡ 47.1 6.4‡
HLA-ABC 97.2 0.4 96.8 1.9 96.1 3.4 98.2 0.6 98.5 0.8 1702.0 87.4 2146.3 183.7§ 2293.7 165.2 2195.0 163.8 2246.3 131.8
HLA-DR 97.0 1.5 93.8 3.9 94.6 4.6 90.2 3.3 95.9 2.5 1660.0 148.9 1843.5 86.0§ 1927.5 93.8 1906.6 173.1 2172.6 200.3‡
CD4 91.7 7.1 88.5 5.8 92.4 3.3 89.3 3.5 87.9 2.7 538.3 72.9 566.8 94.4 802.4 58.7‡ 819.6 59.5‡ 815.8 44.8‡
CD11c 96.5 3.3 94.9 3.2 96.6 3.5 94.2 3.4 99.4 0.2 605.7 13.6 609.3 19.1 606.9 16.6 606.9 20.9 611.7 8.2
CD123 43.4 5.6 38.7 13.9 48.3 19.9 65.4 12.1§ 68.1 2.9§ 70.8 9.3 58.4 19.2 61.8 24.0 95.6 26.1§ 111.5 11.1§
DCs generated in vitro by culture of CD34 cells with GM-CSFIL-4Flt3LTNF- (basal cocktail) plus either SCF or IL-16 or TPO or IL-16TPO were analyzed after 14
days as described in “Materials and methods.” Results report the mean SD of 16 independent experiments. CD11c and CD123 were performed on 5 experiments.
BC indicates basal cocktail.
*Compared with BC.
†Compared with SCF.
‡P  .005 (t test for independent samples).
§P  .05.
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the presence of IL-16 (mean  SEM, 5.2%  0.4%) than in the
presence of the basal cocktail alone (25.4%  1.8%; P  .001) or
with SCF (13.3%  2.0%; P  .004), TPO (15.6%  0.9%;
P  .001), or IL-16 plus TPO (24.0%  0.8%; P  .001). More-
over, after 7 days of culture the percentage of cells already
expressing CD1a was significantly higher in the presence of IL-16
(mean  SEM, 81.4%  1.2%) than in the presence of the basal
cocktail alone (76.1%  6.4%), or with SCF (66.3%  2.7%;
P  .001), TPO (71.4%  1.6%; P  .001), or IL-16 plus TPO
(74.4%  1.6%; P  .005). After 14 days of culture, the superior
efficiency of IL-16 in the differentiation process of DCs was still
more evident when the yield of DCs generated in vitro, obtained
by multiplying the percentage of CD1a cells for the absolute
number of viable cells, expressed as fold increase, was consid-
ered (Figure 1D).
Next, we investigated whether the effects of IL-16 were mainly
exerted on the CD34 subpopulation that expresses CD4.15 To this
purpose, we cultured CD34CD4 and CD34CD4 sorted cells with
the basal cocktail in the presence or absence of IL-16. As shown in
Figure 2A, IL-16 induced a cell expansion of the CD34CD4 cells
significantly higher than the basal cocktail alone (fold increase, mean
SEM, 46.77 5.80 versus 33.28 5.22; paired Wilcoxon signed rank
test; P .006). The effects of IL-16 on cell expansion of CD34CD4
cells were only marginal (30.03 4.40 versus 25.96 4.02; P not
significant). Similar results were observed when the yield of DCs was
considered (Figure 2B).
Immunophenotype of cultured cells
The immunophenotype of the cells cultured in the presence of the
different cytokine combinations was analyzed after 7 and 14 days
of culture. As shown in Table 1, the percentage of cells still
expressing CD34 or CD14 at the end of the culture was negligible
in all the culture conditions, except for culture with the basal
cocktail alone. The contamination of lymphocytes (CD3 or
CD19) and megakaryocytes (CD41) was also negligible ( 1%)
in all the conditions tested and granulocytes (CD15) did not
exceed 10%, without differences among treatments.
Compared with SCF-DCs, IL-16-DCs, TPO-DCs, and IL-16/
TPO-DCs appeared more activated because they showed increased
expression of the costimulatory molecules CD80, CD86, and CD40
(Table 1). IL-16-DCs had the most activated profile, with expres-
sion of CD80 as well CD40 significantly higher than TPO-DCs
(P  .003 and P  .001, respectively) and IL-16/TPO-DCs
(P  .001 in both cases). As shown in Table 1, IL-16-DCs,
TPO-DCs, and IL-16/TPO-DCs appeared also more mature than
SCF-DCs, as assessed by expression of the maturation marker
CD83. Again, IL-16-DCs were the most mature, with CD83
expression significantly higher than TPO-DCs (P  .001) and
IL-16/TPO-DCs (P  .001). In 5 cases we analyzed the expression
of the plasmacytoid marker CD123 and myeloid marker CD11c.
TPO-DCs and IL-16/TPO-DCs had higher expression of CD123
than DCs grown in the absence of TPO (compared with SCF-DCs:
P  .018 and P  .012, respectively). CD123 was coexpressed
with CD11c, which was present on the majority of DCs in all the
culture conditions (Table 1).
The immunophenotypic characterization of the cells obtained
by culture of CD34CD4 and CD34CD4 sorted cells docu-
mented a progressive expression of CD4 molecule on the surface of
the CD34CD4 subpopulation (CD4 cells, 75.9%  9.18% at
day 7; 85.4%  4% at day 14), both in the absence and presence of
IL-16. A representative time-course experiment is shown in Figure
2C. As in the case of unfractioned cells, also in the sorted cell
preparations IL-16 induced a higher expression of the activation
and maturation markers than the basal cocktail alone, with similar
patterns observed in the CD34CD4 and CD34CD4 cultures
(data not shown).
Antigen capture capacity of DCs
The capacity of DCs to take up antigens was measured in 2 systems
using FITC-dextran, as an indicator of mannose-receptor (MR)–
mediated endocytosis, and CMFDA-labeled apoptotic cells, as an
indicator of phagocytosis. DCs obtained by culture with IL-16 or
TPO were as efficient as SCF-DCs, as a control, in capturing
antigens. In fact, similar levels of FITC-dextran uptake were
presented by SCF-DCs (MFI, 41.2  1.7, mean  SEM of 5
independent experiments), IL-16-DCs (39.3  1.7), TPO-DCs
(35.9  2.1), and IL-16/TPO-DCs (37.0  3.0). Similarly, phago-
cytosis of CMFDA-labeled apoptotic cells ( 70% dead cells as
determined by PI and AO staining), assessed by flow cytometry as
the percentage of CD1a-labeled DCs that expressed the green dye
CMFDA and confirmed by the increased granularity of the
double-positive population at forward scatter/side scatter analysis,
did not differ among DCs obtained with different cytokine combi-
nations (data not shown).
Lymphocyte proliferation induced by DCs
Next, we evaluated the allostimulatory proprieties of the DCs
obtained by culture in the different cytokine combinations. To this
Figure 2. Cell proliferation and differentiation of CD34/CD4 and CD34/CD4 sorted cells culture with or without IL-16. (A) After 14 days, the total number of cells
expanded in vitro from CD34/CD4 cells, but not from CD34/CD4 cells, in the presence of IL-16 added to the basal cocktail was higher than in the presence of the cocktail
alone. The mean fold increase over cell number plated on day 0 is shown. Mean SEM from 10 independent experiments. (B) After 14 days, the number of DCs expanded in
vitro from CD34/CD4 cells, but not from CD34/CD4 cells, in the presence of IL-16 added to the basal cocktail was higher than in the presence of the cocktail alone. The
mean fold increase is shown. Mean  SEM from 10 independent experiments. Comparison between treatments performed with the paired Wilcoxon signed rank test. (C)
CD34/CD4 sorted cells grown in the presence of basal cocktail alone (broken line) or with IL-16 (solid line) showed a progressive expression of CD4 molecule on their
surface. One representative of 2 independent experiments is shown.
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purpose, the direct pathway of alloantigen presentation was
assessed in mixed leukocyte reaction as BrdU incorporation by
allogeneic, monocyte-depleted PBMCs. As shown in Figure 3A-B,
IL-16-DCs and TPO-DCs showed excellent allostimulatory activ-
ity, even superior to that of the control SCF-DCs (percent BrdU
lymphocytes, mean  SEM of 9 independent experiments: SCF-
DCs, 11.22  1.40; IL-16-DCs, 14.61  1.87, paired Wilcoxon
signed rank test compared with SCF-DCs, P  .005; TPO-DCs,
13.00  1.55, P  .008). Surprisingly, IL-16/TPO-DCs were un-
able to stimulate the proliferation of allogeneic T-cells (0.68 
0.22, P  .006). In a few experiments, we analyzed the surface
expression of the activation marker CD25 by T cells that had been
cocultured in primary allogeneic culture either with IL-16/TPO-
DCs or with standard immunogenic SCF-DCs. We found that the
reduced T-cell proliferative response induced by IL-16/TPO-DCs
was paralleled by a reduced activation of T cells (percent CD25
lymphocytes, mean  SEM of 3 independent experiments: SCF-
DCs, 25.99  2.84; IL-16/TPO-DCs, 2.18  0.49). To further
determine whether IL-16/TPO-DCs induced tolerance of naive
alloreactive T cells, we tested the proliferative response of T cells
in a 2-step culture system. As shown in Figure 3C, T cells
cocultured with SCF-DCs in the first coculture responded robustly
to rechallenge with the same stimulators. In contrast, the T cells
cocultured with IL-16/TPO-DCs in the first culture were hypore-
sponsive to further stimulation with SCF-DCs. To better define the
role of IL-16 and TPO in conditioning the tolerogenic properties of
IL-16/TPO-DCs, we performed kinetic experiments in which IL-16
and TPO were added to or removed from the cultures at different
times during the differentiation process of DCs. As shown in Figure
4A, the removal of IL-16 plus TPO early or late during the first
week of culture of IL-16/TPO-DCs was enough to generate DCs
endowed with excellent allostimulatory capacity. Figure 4B shows
that the single removal of either IL-16 or TPO early or late during
the first week of culture was enough to restore the allostimulatory
capacity of IL-16/TPO-DCs. Therefore, the concomitant presence
of IL-16 and TPO during the first 7 days of coculture was required
to induce the differentiation of IL-16/TPO-DCs lacking T-
stimulatory activity. We next investigated the effects of IL-16/TPO
combination on sorted CD34/CD4 and CD34/CD4 cell sub-
populations. As shown in Figure 4C, we observed that IL-16 plus
TPO induced from both cell subsets the generation of DCs unable
to stimulate the proliferation of allogeneic T cells.
Last, we analyzed the ability of DCs to present influenza virus
vaccine (FLU), as a soluble antigen, to autologous lymphocytes.
We measured BrdU incorporation by autologous CD4 lympho-
cytes cultured with FLU-pulsed DCs. As shown in Figure 5, the
excellent APC capacity of IL-16-DCs and TPO-DCs observed in
mixed lymphocyte reaction (MLR) was confirmed in this experi-
mental model. On the other hand, IL-16/TPO-DCs were unable to
induce lymphocyte proliferation on presentation of FLU, thus
confirming the tolerogenic profile of these DCs.
Cytokine production by DCs and T cells
DC-derived cytokines were measured by ELISA in the superna-
tants of unstimulated DC cultures. Figure 6A shows kinetic
Figure 4. Effects of IL-16/TPO combination on the generation of tolerogenic
DCs. The allostimulatory activity of DCs was tested in primary cultures, using
monocyte-depleted PBMCs. (A-B) Effects of the presence of IL-16 and TPO at
different times of culture. The concomitant presence of IL-16 and TPO during the first
7 days of culture was required to induce the differentiation of tolerogenic DCs. The
mean  SEM from 3 independent experiments is shown. (C) Effects of IL-16/TPO
combination on sorted cell subpopulations. The presence of IL-16 plus TPO induced
the generation of tolerogenic DCs, which were unable to stimulate the proliferation of
allogeneic T lymphocytes, from both CD34/CD4 (top row) and CD34/CD4
(bottom row) cells. Proliferating lymphocytes identified as CD4/BrdU double-
positive cells. One representative of 4 independent experiments is shown.
Figure 3. Induction of lymphocyte proliferation in primary and secondary
allogeneic cultures. (A) The allostimulatory activity of DCs obtained in the different
cytokine combinations was tested in primary cultures, using monocyte-depleted
PBMCs. Proliferating lymphocytes were identified in density plots as CD4/BrdU
double-positive cells. (B) In primary cultures, IL-16-DCs and TPO-DCs showed
higher allostimulatory activity than control SCF-DCs, whereas IL-16/TPO-DCs were
unable to stimulate the proliferation of allogeneic T lymphocytes. The mean  SEM
from 9 independent experiments is shown. IL-16-DCs, TPO-DCs, and IL-16/TPO-
DCs compared with SCF-DCs with the paired Wilcoxon signed rank test. (C) Tested in
a 2-step culture system, IL-16/TPO-DCs induced tolerance of cocultured T cells.
Purified naive T cells were cultured alone (left column) or cocultured with either
SCF-DCs (center column) or IL-16/TPO-DCs (right column). After 5 days, the T cells
were harvested, washed, and rested for 2 days. The rested T cells from primary
cultures were subsequently rechallenged with SCF-DCs. Proliferation of T lympho-
cytes was assessed as BrdU incorporation after 4 days. One representative of 3
independent experiments is shown.
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experiments aimed at comparing cytokine production at different
time points during the differentiation process of DCs grown in the
different cytokine combinations. The analysis of cytokine produc-
tion at the end of the differentiation process indicated that, as
shown in Figure 6B, tolerogenic IL-16/TPO-DCs produced mark-
edly higher levels of the immunosuppressive cytokines TGF-
 and
IL-10, and lower levels of the stimulatory cytokine IL-12p70, than
standard immunogenic SCF-DCs. Also IL-16-DCs and TPO-DCs
produced higher levels of IL-10 than SCF-DCs, but at lower levels
than IL-16/TPO-DCs. Unlike the other types of DCs, IL-16/TPO-
DCs also produced IFN-. As shown in Figure 6B, the pattern of
cytokine production of SCF-DCs and IL-16/TPO-DCs obtained
from either CD34/CD4 or CD34/CD4 sorted cells was similar
to that of DCs obtained from unfractionated cells. The production
of IFN-	 was negligible by DCs cultured in all the cytokine
combinations (not shown).
To better characterize the effects of IL-16/TPO-DCs compared
with standard SCF-DCs on T lymphocytes, we analyzed the
production of cytokines involved in cell activation and prolifera-
tion, by T lymphocytes cocultured with DCs. Because we per-
formed bidirectional allogeneic cultures, we analyzed by flow
cytometry intracellular cytokine expression by T lymphocytes. In
accordance with the proliferative responses, we observed that
following culture with SCF-DCs T lymphocytes expressed IL-2
and IFN-	, whereas following culture with IL-16/TPO-DCs they
failed to express both cytokines (Figure 6C). T-cell expression of
IL-10 was undetectable on culture with either stimulator.
Expression of DC-SIGN and of the inhibitory molecules ILT-2,
ILT-3, and ILT-4 on DC surface
To investigate other mechanisms possibly contributing to the
tolerogenic profile of IL-16/TPO-DCs, we next examined the
expression on the DC surface of additional molecules involved in
DC/T-cell interactions. Therefore, we analyzed the DC expression
of the C-type lectin DC-SIGN and found that although the
percentage of DCs expressing DC-SIGN in IL-16-DCs and TPO-
DCs was similar to that observed in the control SCF-DCs (percent
DC-SIGN DCs, mean  SEM of 4 independent experiments:
57.6  4.4, 52.6  3.1, and 45.1  8.8, respectively), the percent-
age of DC-SIGN in IL-16/TPO-DCs was markedly decreased
(20.5  1.1, Wilcoxon signed rank test, P  .010; Figure 7).
DC-SIGN expression was directly correlated with lymphocyte
proliferation induced in allogeneic cultures (Spearman rank corre-
lation: Rho  0.626, P  .016). Moreover, we examined DC
Figure 6. Production of cytokines by DCs and T cells. (A) Production of cytokines at different time points during the differentiation process of DCs grown in different cytokine
combinations. CD34 cells were cultured in the presence of SCF (Œ), IL-16 (), TPO (F), or IL-16 plus TPO (f), and the released cytokines were measured in the supernatants
by ELISA. The concomitant presence of IL-16 and TPO induced the production of higher levels of TGF-
, IL-10, and IFN-, and lower levels of IL-12p70, which became
increasingly evident during the second week of culture. The mean  SEM from 2 independent experiments is shown. (B) Production of cytokines by DCs. Unfractionated
CD34 cells, CD34/CD4, and CD34/CD4 sorted cells were grown in the presence of the indicated cytokine combinations for 14 days, and the released cytokines were
measured in the supernatants by ELISA. IL-16/TPO-DCs obtained either from unfractionated CD34 cells or from CD34/CD4 or CD34/CD4 cells produced higher levels of
TGF-
, IL-10, and IFN-, and lower levels of IL-12p70, than the other types of DCs. Mean SEM from 4 independent experiments. IL-16-DCs, TPO-DCs, and IL-16/TPO-DCs
compared with SCF-DCs with the paired Wilcoxon signed rank test; *P  .05. (C) Production of cytokines by T cells cocultured with IL-16/TPO-DCs compared with SCF-DCs.
Monocyte-depleted PBMCs were cultures alone (left columns), or with SCF-DCs (central columns), or with IL-16/TPO-DCs (right columns). After the indicated days of DC/T
coculture, T cells were reactivated with PMA and ionomycin for 5 hours, and their intracellular expression of cytokines detected by flow cytometry. Gated on CD4 T cells,
density plots show the expression of IFN-	 and IL-2 (upper row) or IL-10 (lower row). Quadrants were set according to the fluorescence intensities of isotype-matched controls.
T cells cocultured with IL-16/TPO-DCs failed to express IL-2 and IFN-	. IL-10 was not expressed in any condition. One representative of 3 independent experiments is shown.
Figure 5. Induction of proliferation of autologous lymphocytes on presentation
of a soluble antigen, FLU. The lack of T-stimulatory activity of IL-16/TPO-DCs was
confirmed when the proliferation of autologous T lymphocytes on presentation of FLU
was tested. The capacity of DCs obtained in the different cytokine combinations to
induce T-cell proliferation was compared. Proliferating lymphocytes were identified in
density plots as CD4/BrdU double-positive cells. Control cultures included mono-
cyte-depleted PBMCs alone (left column), cocultured with unpulsed DCs (middle
column), or antigen-specific proliferation assessed in cultures with FLU-pulsed DCs
(right column). The numbers represent the percentage of cells in each quadrant. One
representative of 3 independent experiments is shown.
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expression of the inhibitory molecules ILT-2, ILT-3, and ILT-4. As
shown in Figure 7, the expression of these molecules was markedly
increased in IL-16/TPO-DCs compared with control SCF-DCs
(percent ILT-2 DCs, 44.3  10.4 versus 15.9  2.8, P  .025;
percent ILT-3 DCs, 33.9  8.1 versus 6.2  0.6, P  .025; per-
cent ILT-4 DCs, 35.3  7.6 versus 4.6  0.2, P  .025). The
expression of ILT-2, ILT-3, and ILT-4 by DCs was inversely
correlated with the proliferative response induced in allogeneic
cultures (ILT-2, Rho  0.798, P  .003; ILT-3, Rho  0.560,
P  .073; ILT-4, Rho  0.661, P  .027).
Discussion
Our data demonstrate for the first time that IL-16, added to a basal
cocktail of cytokines composed of Flt3L, GM-CSF, IL-4, and
TNF-, can induce human CD34 cells obtained from G-CSF–
mobilized blood of adult individuals, to proliferate and differentiate
into fully mature DCs. Compared with other growth factors,
namely, SCF (used as a control), TPO, or IL-16 plus TPO, IL-16
exerted this function more efficiently, as indicated by the observa-
tion that after 14 days of culture the total number of cells expanded
in vitro in the presence of IL-16 was higher than in the presence of
the other growth factors. IL-16 also induced the differentiation of
higher numbers of CD1a DCs than did the other growth factors.
The physiologic in vivo relevance of these results is possibly
supported by the notion that CD34 cells are able to secrete IL-16
themselves, thus suggesting that IL-16 could play a key role, with
other endogenously secreted factors, in the biology of early
hematopoietic cells.23 A better understanding of the role of IL-16 in
regulating the biology of human hematopoietic cells will rely on a
fine characterization of the structure and the function of this
molecule, both of which are currently under intense investigation.
Next, we proceeded to the functional characterization of the
DCs obtained with the different cytokine combinations. We found
that IL-16-DCs had a more activated and mature immunopheno-
type than the other DCs, as assessed by a higher expression of the
costimulatory molecules CD80, CD86, CD40, and the maturation
marker CD83. Notably, this higher stage of maturation did not
affect the ability of these cells to internalize antigens. In fact, the
DCs obtained with all the cytokine combinations showed similar
good capacities to capture antigens either by MR-mediated endocy-
tosis or by phagocytosis. Moreover, IL-16-DCs were endowed with
excellent APC function, measured as allostimulatory activity and
ability to induce T-cell proliferation on presentation of FLU. In this
respect, IL-16-DCs were quite similar to SCF-DCs, used as a
control, and to TPO-DCs. All together, these results seem to
suggest that the substitution of standard SCF with either IL-16 or,
to a lesser extent, TPO may represent alternative tools to improve
the efficiency of in vitro generation of immunogenic DCs.
IL-16/TPO-DCs were tolerogenic. In fact, in primary cultures
they were unable to stimulate the proliferation of either allogeneic
T cells or autologous T cells on presentation of influenza virus
vaccine. This lack of proliferation resulted from the ability of
IL-16/TPO-DCs to induce an anergic state in T cells, documented
by low expression of CD25, IL-2, and IFN-	 in cocultured T
lymphocytes, which persisted when IL-16/TPO-DC–conditioned T
cells were rechallenged with immunogenic SCF-DCs. The concomi-
tant presence of IL-16 and TPO during the first 7 days of culture
was required to induce tolerogenic DCs, as indicated by kinetic
experiments. Because treatment of developing DCs with TGF-
 or
IL-10 or both promotes the generation of tolerogenic DCs,24-26 we
asked whether induction of these cytokines might represent a
possible mechanism used by IL-16/TPO combination to influence
DC differentiation. We found indeed that the levels of both TGF-

and IL-10 were higher in the milieu of developing IL-16/TPO-DCs
than in the milieu of the other DCs. Next, we considered the
possible mechanisms used by IL-16/TPO-DCs to induce tolerance
of cocultured T-cells. The tolerogenic properties of IL-16/TPO-
DCs could not be ascribed to an immature state because their
surface expression of HLA and costimulatory molecules was not
lower than expression on immunogenic DCs grown in the other
cytokine combinations. However, “semimature DCs” have been
described that induce T-cell tolerance despite their mature pheno-
type if they produce low levels of IL-12p70.24,27,28 Indeed, our
results indicated that IL-16/TPO-DCs produced markedly lower
levels of IL-12p70 than the other types of DCs. This finding,
together with the observation that IL-16/TPO-DCs produce high
levels of the immunosuppressive cytokines TGF-
 and IL-10, may
suggest that an altered pattern of cytokine production may contrib-
ute to the tolerogenic properties of IL-16/TPO-DCs.
To further investigate other possible mechanisms used by
IL-16/TPO-DCs to induce T-cell tolerance, we evaluated their
surface expression of additional molecules involved in DC/T-cell
interactions. DC-SIGN (CD209) is a recently identified DC-
specific adhesion receptor belonging to the C-type lectin family,
involved in the control of many functions of DCs including
initiation and regulation of interactions between DCs and T
cells.29,30 Our results indicated that the expression of DC-SIGN was
markedly decreased on IL-16/TPO-DCs and was directly corre-
lated with the intensity of the induced T-cell proliferation. ILT-2,
ILT-3, and ILT-4 belong to a family of inhibitory receptors that can
be expressed on many cell types; it has been recently demonstrated
that the expression of these molecules on DCs, induced by
regulatory T cells, renders DCs tolerogenic.31,32 We analyzed the
expression of ILT molecules on our DCs and observed indeed that
the expression of ILT-2, ILT-3, and ILT-4 was increased on
IL-16/TPO-DCs and was inversely correlated with the induced
proliferation of allogeneic T cells. Therefore, our results may
suggest that low surface expression of DC-SIGN and high expres-
sion of ILT inhibitory molecules may represent additional mecha-
nisms possibly involved in the tolerogenic properties of
IL-16/TPO-DCs.
Figure 7. Expression of DC-SIGN and of ILT-2, ILT-3, and ILT-4 by DCs. The
frequency of DCs expressing DC-SIGN was markedly lower in IL-16/TPO-DCs
compared with the DCs grown in the other cytokine combinations. In the same cells
the frequency of DCs expressing ILT-2, ILT-3, and ILT-4 was markedly higher. The
mean  SEM of 4 independent experiments is shown. Comparison between
treatments performed with the paired Wilcoxon signed rank test.
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Our results seem to indicate that the IL-16/TPO combination
does condition the development of a distinct tolerogenic DC
subtype that shares some features, but not others, with other defined
DC subsets. In fact, similarly to Langerhans-type DCs, which are
developed by culture of CD34 cells in the presence of exogenous
TGF-
 combined with GM-CSF, TNF-, Flt3L, and SCF,33,34
IL-16/TPO-DCs express the Langerhans cell-restricted molecule
CD1a and lack DC-SIGN expression. But, unlike Langerhans-type
DCs, which are immature DCs, they have a mature phenotype.
Similarly to plasmacytoid DCs that can be developed by culture of
CD34 cells in the concomitant presence of Flt3L and TPO,35
IL-16/TPO-DCs express CD123 and produce IFN-. But, unlike
these plasmacytoid DCs, they coexpress the myeloid marker
CD11c. Notably, the possibility that these plasmacytoid features
may contribute to the tolerogenic properties of IL-16/TPO-DCs
appears unlikely because DCs coexpressing CD123 and CD11c and
producing IFN-, obtained by culture of monocytes in GM-CSF
plus IFN-, are endowed with excellent APC function, as we
recently reported elsewhere.20
Last, we considered the effects of the cytokine combinations on
the sorted subpopulations enriched in CD34CD4 and
CD34CD4 cells. Our results clearly indicate that IL-16 is more
effective on the CD34CD4 subpopulation. This finding is not
surprising because secreted IL-16 is known to be the natural
soluble ligand of CD4 molecule.36 Indeed, we observed that culture
of CD34CD4 cells in basal cocktail with or without IL-16
induced a progressive surface expression of CD4. Because CD4
expression was observed on a relevant percentage of cells after 3 to
4 days of culture, it may be argued that the proliferative effect of
IL-16 on CD4 cells is mainly exerted during the first days of
culture. Interestingly, the effects of IL-16 compared with basal
cocktail were more marked on unfractionated cells, containing both
CD4 and CD4 cells, than on sorted CD34CD4 cells. We
suggest that synergistic cooperation between different cell popula-
tions, with the possible involvement of other soluble factors, may
be promoted by IL-16 in unfractionated cells and may be lost when
the cells are sorted. On the other hand, IL-16/TPO combination was
similarly effective on CD34CD4 and CD34CD4 subpopula-
tions in inducing the generation of tolerogenic DCs. Because IL-16
plus TPO exert their effects during the first days of culture, the
possibility that some of the effects of IL-16 may be mediated not
only by CD4 receptor but also by other coactivators, as already
reported elsewhere,37-39 may be considered. Further experiments
will be required to clarify this point.
In conclusion, in this study we provide evidence that IL-16 and
TPO may represent new tools for the in vitro generation of DCs
from CD34 progenitors. In different combinations with other
cytokines they can improve the efficiency of generation of immuno-
genic DCs, or induce the generation of tolerogenic DCs that may
aid the exploration of new therapeutic strategies to promote
tolerance to autoantigens and prevent disease development.
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